我国创新药研发模式与价值评估(I)

创新药研发对企业研发能力要求高,目前我国大部分药企仍然处于仿创阶段,但随着政策环境的改善,国家不断释放鼓励创新信号, 创新型药企不断涌现,传统药企积极布局,创新药物迎来发展机遇。借鉴国外创新药研发经验,探讨我国创新药的 3 种研发模式及估值方法, 解析创新药研发的机遇与风险。

Development Modes and Valuation for Innovative Drugs in China ( I )

At present, most of domestic pharmaceutical companies are still committed to the development of generic drugs, as strong research and development capacity is responsible for the development of innovative drugs. With the implementation of favorable policies and the release of encouraging messages from the government, innovative pharmaceutical companies are emerging, and traditional pharmaceutical companies are also taking an active part in this area. As a result, great opportunities arise for the development of innovative drugs in China. Based on the experience of drug innovation in foreign countries, three development modes and valuation method for innovative drugs in China were discussed, and the opportunities and risks in domestic drug innovation were also analyzed in this report.